Kautzner Josef, Peichl Petr
Department of Cardiology, Institute for Clinical and Experimental Medicine - IKEM, Prague, Czech Republic.
Department of Cardiology, Institute for Clinical and Experimental Medicine - IKEM, Prague, Czech Republic.
Int J Cardiol. 2017 Jun 15;237:29-33. doi: 10.1016/j.ijcard.2017.03.135. Epub 2017 Apr 1.
Since ventricular arrhythmias are a common cause of sudden cardiac death (SCD), treatment for ventricular arrhythmias is the target area of interest in research field. Among different means to prevent ventricular arrhythmias, catheter ablation (CA) has emerged as an effective therapeutic method. CA can decrease the likelihood of SCD in the following arrhythmia categories: 1) idiopathic ventricular fibrillation (VF) that is usually triggered by premature ventricular beats originating in the Purkinje fibres; 2) VF in subjects with structural heart disease, especially after myocardial infarction, that is triggered by premature ventricular beats from surviving Purkinje fibres; 3) Brugada syndrome in which modification of an epicardial substrate in the right ventricular outflow tract might be the most promising strategy; 4) recurrent monomorphic ventricular tachycardias in the setting of structural heart disease; 5) ventricular preexcitation in which CA appears to be a method of choice in high risk patients, regardless of the presence or absence of symptoms. In conclusion, CA is a therapeutic method that may prevent SCD in different subsets of patients. Better understanding of mechanisms and substrates may further improve the rate of success and/or broaden such prophylactic indications.
由于室性心律失常是心脏性猝死(SCD)的常见原因,因此室性心律失常的治疗是研究领域关注的目标。在预防室性心律失常的不同方法中,导管消融(CA)已成为一种有效的治疗方法。CA可降低以下心律失常类型发生SCD的可能性:1)通常由起源于浦肯野纤维的室性早搏触发的特发性心室颤动(VF);2)结构性心脏病患者,尤其是心肌梗死后,由存活的浦肯野纤维发出的室性早搏触发的VF;3)右心室流出道心外膜基质改变可能是最有前景策略的Brugada综合征;4)结构性心脏病背景下的复发性单形性室性心动过速;5)室性预激,无论有无症状,CA似乎都是高危患者的首选治疗方法。总之,CA是一种可预防不同亚组患者发生SCD的治疗方法。对机制和基质的更好理解可能会进一步提高成功率和/或拓宽此类预防适应症。